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Background and purpose   The Artelon CMC spacer is designed 
for surgical treatment of osteoarthritis (OA) in the carpometacar-
pal joint of the thumb (CMC-I). Good results using this degrad-
able device were previously presented in a pilot study. We now 
present results from a larger randomized, controlled, multicenter 
study.
Patients and methods   109 patients (94 females) with a mean 
age of 60 (42–83) years, suffering from painful CMC OA, were 
included in the study at 7 centers in Sweden. The patients were 
randomized  to Artelon  CMC  spacer  (test,  n  =  72)  or  tendon 
arthroplasty (control, n = 37) at a ratio of 2:1. Perceived pain 
was recorded on a visual analog scale (VAS) before treatment 
and after 3, 6, and 12 months, when measuring maximal tripod 
pinch strength (primary outcome measure). In addition, range 
of  motion,  radiographic  findings,  and  functional  testing  were 
recorded pre- and postoperatively. 
Results  Swelling and pain were more common in the test group 
and 6 implants were removed because of such symptoms. 5 of 
these patients did not receive antibiotics preoperatively according 
to the study protocol. In a per-protocol analysis, i.e. patients with-
out signs of concomitant OA in the scaphoid-trapezium-trapezoid 
(STT) joint and those in the test group who received antibiotics, 
the mean difference in tripod pinch strength increase, adjusted 
for baseline, was 1.4 kg in favor of the test group (not statistically 
significant). Statistically significant pain relief was achieved in 
both groups, with perceived pain gradually decreasing during the 
follow-up period. In the intention-to-treat analysis but not in the 
per-protocol analysis, significantly better pain relief (VAS) was 
obtained in the control group. Patient-perceived disability evalu-
ated by the DASH questionnaire improved in both groups.
Interpretation   The Artelon CMC spacer did not show superior 
results  compared  to  tendon  interposition  arthroplasty.  Proper 
use of preoperative antibiotics and a thorough patient selection 
appear to be important for the results.

Surgical treatment of carpometacarpal (CMC) osteoarthritis 
(OA) includes several different techniques, which have been 
compared  in  previous  studies  (Gervis  1949, Wolock  et  al. 
1989, Amadio and De Silva 1990, Kuschner and Lane 1996, 
Gibbons et al. 1999, Mureau et al. 2001). Soft tissue interpo-
sition, with or without ligament reconstruction (Burton and 
Pellegrini 1986, Froimson 1987, Weilby 1988, Sigfusson and 
Lundborg 1991), and silicone elastomer arthroplasty (Swan-
son et al. 1981) result in good pain relief, but some long-term 
studies  have  shown  disabling  weakness  of  the  pinch  grip 
(Tomaino et al. 1995, Hartigan et al. 2001).
Endoprostheses  have  been  used,  either  as  a  total  joint 
replacement with preserved os trapezium or as an implant 
replacing os trapezium (Regnard 2006). Both implant designs 
are associated with subluxation, material fatigue, and occur-
rence of wear debris causing adverse tissue reactions (Swan-
son et al. 1981, Sollerman et al. 1993, Bezwada et al. 2002, 
Perez-Ubeda et al. 2003). 
Nilsson  et  al.  (2005)  presented  a T-shaped  CMC  device 
made of a degradable polyurethane urea (Artelon) and evalu-
ated the results in a pilot study. The device has two modes 
of action: it stabilizes the CMC joint by augmentation of the 
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bone. The selection of a degradable biomaterial for the CMC 
spacer device was based on a biological approach to support 
the local tissue repair. The purpose of the device was to pro-
vide a scaffold for tissue ingrowth and to prevent impingement 
between the bones of the CMC joint. In the pilot study, this 
implant showed superior results compared to tendon interposi-
tion arthroplasty (Nilsson et al. 2005).
A larger randomized, controlled, multicenter study has now 
been performed to further evaluate the benefits of this method. 
Patients included in the study were randomized to the CMC 
joint spacer or tendon interposition arthroplasty surgery at a 
ratio of 2:1. Here we present the 1-year results from this study. 
Patients and methods
A randomized, controlled, and observer-blinded multicenter 
study was started at 7 Swedish hospitals. The study plan was 
reviewed and approved by the local university ethics com-
mittees in Göteborg (S 301-01; T 356-03), Örebro (890/01), 
Uppsala (Ups 01-365), Lund (LU 544-01), Linköping (LIU 
02-402), and Stockholm (KI 01-354) according to the Decla-
ration of Helsinki of 1975, as revised in 2000. 
The study included 109 consecutive patients (111 thumbs) 
with painful and radiographically verified OA (Eaton stage 
1–3) in the CMC joint (Eaton and Glickel 1987). Exclusion 
criteria were OA in the scaphoid-trapezium-trapezoid (STT) 
joint,  serious  illness,  an  ongoing  infection,  or  malignancy 
within the previous 10 years. After giving informed consent, 
the patients were randomized to the Artelon CMC spacer (test 
group) or tendon interposition arthroplasty (control group) at 
a ratio of 2:1 (Figure 1), according to a randomization list and 
by using closed envelopes. The test group had 72 patients (61 
females) and the control group had 37 patients (33 females). 
Their mean ages were 59 (42–77) years and 61 (45–83) years, 
respectively. The patients were operated on between March 
2002 and August 2004. The numbers of thumbs operated on 
at the 7 hospitals varied between 7 and 23. The dominant 
hand, in most cases the right hand, was operated in 31 and 22 
patients in the test and control group, respectively (42% and 
59%). 6 patients were withdrawn from the test group before 
the 1-year follow-up due to reoperation and 1 patient because 
of serious illness. 2 patients in each group did not come to the 
1-year follow-up visit (Figure 1).
The pre- and postoperative examinations included both sub-
jective and objective tests, and they were performed by blinded 
observers, i.e. the observers carrying out the follow-up investi-
gations were not informed about which surgical procedure the 
individual patient had undergone. Clinical instability, swell-
ing, bleeding, erythema, and infections were recorded at all 
visits.
Pain was registered according to a visual analog scale (VAS; 
0 = no pain, 10 = unbearable pain), when measuring maximal 
tripod and key pinch. Pinch strength—both tripod (primary 
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outcome measure) and key pinch—was measured with a pinch 
gauge (North Coast Medical Inc., Morgan Hill, CA). Transverse 
volar grip strength was measured with a dynamometer (Jamar; 
Sammons Preston Inc., Bolingbrook, IL). Measurements were 
made with the patient sitting in a chair with the elbow rest-
ing on a table. Furthermore, radial and palmar thumb abduc-
tion were measured with a goniometer and recorded between 
the first and second metacarpal. Patient-perceived disability 
was evaluated using the DASH questionnaire (Disability of 
the Arm, Shoulder, and Hand) (Turchin et al. 1998, Atroshi et 
al. 2000). The scores from all items were used to calculate a 
total score ranging from 0 (no disability) to 100 (most severe 
disability). The patients’ satisfaction with treatment and their 
subjective experiences were recorded on a scale from 1 (not at 
all) to 5 (very satisfied/very good). 
Radiography was performed pre- and postoperatively with 
dedicated postero-anterior (PA) and lateral views of the thumb 
and first metacarpal, also including the trapezium and scaph-
oid. Additional oblique or Eaton projections were obtained 
when needed. All preoperative and 1-year radiographs were 
evaluated by an independent observer. The joint space width 
of the CMC-I joint and the degree of subluxation of the first 
metacarpal were measured with a magnifying loupe with a 
sub-millimeter graded caliper on films, and with measuring 
tools (software) on digital images. The degree of OA in the 
CMC-I joint was graded according to Eaton (North and Eaton 
1983, Eaton and Glickel 1987).
Surgical technique
The  Artelon  material  is  manufactured  by  Artimplant  AB, 
Sweden, and has been described in earlier reports (Gisselfält 
et al. 2002, Liljensten et al. 2002, Gretzer et al. 2003). The 
Artelon CMC spacer device is T-shaped with a vertical spacer 
serving as an interposition in the CMC joint, and 2 horizontal 
wings augmenting the dorsal joint capsule in order to prevent 
dorso-radial migration of the proximal metacarpal (Figure 2).
Implantation of the spacer was performed through a dorsal 
approach, exposing the CMC joint with a proximal-based cap-
sular incision (Nilsson et al. 2005). Approximately 2 mm of 
the distal surface of the trapezium and any osteophytes were 
excised with a chisel. The device was inserted with the vertical 
part into the joint space and the wings anchored to cancellous 
bone on each side of the joint. Fixation was achieved with 
non-resorbable osteosutures.
In the control group, the trapezium was resected in all cases 
but the tendon interposition was performed with different tech-
niques according to the established routine at each center. The 
abductor pollicis longus (APL) tendon was used for interposi-
tion in 22 cases (Sigfusson and Lundborg 1991), the extensor 
carpi radialis longus (ECRL) tendon in 6 cases (Necking and 
Eiken 1986), and the Burton procedure in 9 cases (Burton and 
Pellegrini 1986). The postoperative treatment was the same in 
all patients with 5–6 weeks of plaster fixation followed by a 
mobilization program.
 
Statistics
The patients were randomly allocated to test group and control 
group at a ratio of 2:1. In order to detect a clinically relevant 
difference of 1 kg in tripod pinch strength between the groups 
after 1 year at a significance level of 0.05 and with a power of 
80%, at least 56 subjects were needed in the test group and 28 
subjects in the control group, assuming the SD in both groups 
to be 0.6 kg. To compensate for any dropouts, 72 subjects 
were randomized to the test group and 36 to the control group. 
Change over time within groups was analyzed with Student’s 
t-test for paired analyses. For comparison between groups in 
change from baseline to 1-year follow-up, analysis of variance 
(ANCOVA) was used with adjustment for baseline values. 
Adjusted  mean  differences  between  groups  are  given  with 
95% confidence intervals (CIs). In 2 patients, both thumbs 
were treated. In 1 of these patients, the thumbs were random-
ized to each of the two groups. The values from both of these 
thumbs are accounted for in the analysis. This would give a 
slightly conservative test. The other patient was randomized 
to the test treatment in both thumbs and the mean of these 2 
measurements was calculated when included in the analyses, 
i.e. the statistical analyses were based on patient as the unit.   
Significance tests were two-tailed and were conducted at the 
5% significance level.
   
Results
Intention-to-treat analysis, i.e. all patients included in 
the study
Tripod pinch strength (primary outcome measure) decreased 
immediately after surgery, but both groups had regained their 
pinch and grip strength after 1 year without any statistically 
significant difference between the groups (Table and Figure 3, 
right panel). Perceived pain decreased significantly during the 
follow-up period in both groups according to the VAS mea-
surements (Figure 3, left panel), with significantly more pain 
relief in the control group (Table). 
Figure 2. The Artelon CMC spacer device with the vertical spacer (A) 
and the 2 horizontal wings (B).240  Acta Orthopaedica 2010; 81 (2): 237–244
The evaluation of 107 available preopera-
tive radiographs (96%) by an independent 
observer revealed no radiographic OA in 1 
case, OA in the CMC-I joint of Eaton stage 
1 in 8 cases (7%), stage 2 in 60 cases (56%), 
stage 3 in 29 cases (27%), and stage 4 in 
9 cases (8%). Except for the latter 9 cases 
with Eaton stage 4, STT OA was seen in 8 
further patients who were graded as being 
Eaton  stage  1–2.  In  total,  the  evaluation 
revealed 17 cases (16%) with osteoarthritic 
changes in the STT joint: 9 in the spacer 
group and 8 in the control group. 
1-year radiographs were available for 57 
patients (90%) in the spacer group. 4 pos-
sible  complications  were  noted:  2  cases 
with a high degree of subluxation, 1 case of 
severe osteoporosis, and 1 patient with pos-
sible osteonecrosis of the trapezium. Post-
operative radiography of all patients in the 
control group did not reveal any abnormali-
ties other than the expected absence of the 
trapezium. 
Pinch and grip strength, and perceived pain at maximal loading
  CMC spacer    Tendon arthroplasty   Difference between groups
  Pre-treatment   12 months    Pre-treatment   12 months    Change 0–12 months
  mean (SD)  mean (SD)  mean (SD)  mean (SD)    Adjusted for baseline
  median (range)   median (range)  median (range)  median (range)   mean   95% CI   p-value
Intention-to-treat   n = 73  n = 63  n = 37  n = 35
Strength
  Tripod pinch (kg)  5.1 (2.4)  5.7 (3.5)  4.5 (2.5)  5.0 (2.1)    0.3  -0.8–1.4  0.6
    5.0 (1.2–15)  5.3 (1–19)  4.0 (1–12)  5.0 (1–9.5)
  Key pinch (kg)  5.7 (2.6)  5.8 (3.0)  5.3 (3.3)  5.2 (2.0)    0.5  -0.6–1.5  0.4
    5.2 (2–14)  5.5 (1.5–19)  4.7 (1–20)  5.0 (2–10)
  Volar grip (kg)  22  (10)  24  (10)  18  (9)  22  (11)   -0.3  -4.1–3.4  0.9
    20  (5–75)  24  (2–57)  17  (1–40)  22  (2–40)
Pain
   Tripod pinch (VAS)  4.4 (2.7)  2.6 (2.7)  5.3 (2.9)  1.3 (2.4)    1.5   0.4–2.5  0.007
    4.3 (0–10)  2.0 (0–10)  5.0 (0–10)  0    (0–9)
  Key pinch (VAS)  4.5 (2.6)  2.6 (2.5)  4.9 (2.6)  1.2 (2.0)    1.4    0.4–2.4  0.005
    4.9 (0–9)   2.0 (0–9)   5.0 (0–10)  0    (0–8)   
Per-protocol  n = 39  n = 36   n = 28   n = 26
Strength 
  Tripod pinch (kg)  5.9 (2.7)  7.0 (3.8)  4.9 (2.8)  5.0 (2.2)    1.4  -0.1–3.0  0.06
    6.0 (1.2–15)  6.5 (2–19)  4.4 (1–12)  5.0 (1–9.5)
  Key pinch (kg)  6.5 (2.9)  6.9 (3.4)  5.4 (3.6)  5.3 (2.1)    1.4  -0.1–2.8  0.07
    6.0 (2–14)  6.3 (3–19)  4.6 (1–20)  5.0 (2–10)
  Volar grip (kg)  24  (11)  27  (11)  20  (9)  23  (10)    0.6  -4.1–5.4  0.8
    22  (5–75)  27  (2–57)  20  (8–40)  24  (6–40)
Pain
  Tripod pinch (VAS)  3.9 (2.8)  2.2 (2.7)  5.4 (3.1)  1.4 (2.2)    1.0  -0.3–2.4  0.1
    3.3 (0–9)  1.0 (0–10)  5.0 (0–10)  0    (0–7)
  Key pinch (VAS)  3.7 (2.7)  2.2 (2.5)  4.9 (2.8)  1.2 (1.8)    1.1     0–2.3  0.06
     3.9 (0–9)   1.5 (0–9)   5.0 (0–10)  0    (0–5) 
Figure 3. The intention-to-treat analysis (i.e. involving all patients included in the study) of 
pain according to VAS (left panel) and strength (right panel) at maximal loading in tripod 
pinch (pinch gauge) before treatment and during 1 year after surgery, for patients treated 
with the Artelon CMC spacer (n = 65) or trapezium excision and tendon interposition (n 
= 35). Dots and error lines show median/mean values and confidence intervals, and the 
p-values are for change up to 1 year. **p < 0.01 for difference between groups.Acta Orthopaedica 2010; 81 (1): 237–244  241
At  the  1-year  follow-up,  mild  to  moderate  swelling  was 
noted in 21 thumbs (32%) in the test group and in 1 thumb 
(3%) in the control group. Complications in the test group 
during follow-up included removal of 6 CMC spacers mainly 
because of pain. In 2 of these cases, infection was suspected 
but bacterial cultures were negative. Histological evaluation of 
the explanted spacers showed no signs of inflammation located 
in close proximity to the Artelon material. In 2 cases, however, 
inflammatory cells could be detected in the surrounding soft 
tissue and near and inside the suture used for fixation, respec-
tively. Other complications in the spacer group were presence 
of pain in 7 other patients at the 6- or 12-month follow-ups. 
No complications related to the treatment were reported in the 
control group.
   
Per-protocol analysis, i.e. patients who followed all 
details in the study protocol
Deviations from the intended study protocol were found in 
40% of the cases (Figure 1) and thus a per-protocol analy-
sis was also performed excluding the following patients: 17 
patients with STT OA—9 in the spacer group and 8 in the 
control group—had been included and 1 patient in the con-
trol group without radiographically verified CMC-I OA, when 
the radiographs were analyzed by the independent observer. 
According to the protocol, 1 dose of preoperative antibiotics 
should have been administered in the spacer group. However, 
46% (33/72) of the patients did not receive this.
In the spacer group, the mean change in tripod pinch strength 
was 1.1 kg (SD 3.8, p = 0.09) after 1 year and in the control 
group it was 0.2 kg (SD 2.3, p = 0.7) (Figure 4, right panel), 
with no statistically significant difference between the groups 
(p = 0.06) (Table). The mean change in key pinch after 1 year 
was 0.4 kg (SD 3.5, p = 0.5) in the spacer group and –0.2 
kg (SD 3.7, p = 0.8) in the control group. The correspond-
ing figures for change in transverse volar grip strength in the 
two groups were 3 kg (SD 11, p = 0.1) and 4 kg (SD 9, p = 
0.01), respectively. The median VAS values of perceived pain 
had become significantly reduced after 1 year in both groups 
(Figure 4, left panel).
The range of motion evaluated as mean radial abduction 
of the thumb increased during follow-up in the spacer group 
from 55° (SD 17) to 60° (SD 20) after 1 year (p = 0.02), and 
mean palmar abduction increased from 54° (SD 17) to 60° 
(SD 18) after 1 year (p = 0.003). The corresponding figures 
in the control group were 48° (SD 15) before treatment to 53° 
(SD 19) after 1 year (p = 0.2) for radial abduction, and 51° 
(SD 16) before treatment to 52° (SD 16) after 1 year (p = 0.8) 
for palmar abduction.
The mean DASH score improved in both groups (Figure 
5). The median decrease in score after 1 year was –26 (–49 
to 1) in the spacer group and –18 (-46 to 1) in the control 
group,  including  only  those  with  surgery  in  the  dominant 
thumb. Patient assessments of their thumb function after 1 
year revealed a score above 3 in 60% (21/35) of the patients 
in the spacer group as compared to 65% (17/26) in the control 
group. The corresponding figures for satisfaction were 66% 
(23/35) and 69% (18/26), respectively.
Figure 5. The DASH outcome in patients treated 
with  the  Artelon  CMC  spacer  (n  =  13)  or  tra-
pezium  excision  and  tendon  interposition  (n  = 
15). The score ranged from 0 (no disability) to 
100 (most severe disability). Only patients with 
surgery in the thumb of the dominant hand are 
included, due to the character of the questions. 
Dots and error lines show mean values and con-
fidence intervals, and the p-values are for change 
up to 1 year.
Figure 4. The per-protocol analysis (i.e. involving patients who followed all details in the 
study protocol) of pain according to VAS (left panel) and strength (right panel) at maximal 
loading in tripod pinch (pinch gauge) before treatment and during 1 year after surgery, for 
patients treated with the Artelon CMC spacer (n = 36) or trapezium excision and tendon 
interposition (n = 26). Dots and error lines show median/mean values and confidence 
intervals, and the p-values are for change up to 1 year.242  Acta Orthopaedica 2010; 81 (2): 237–244
Discussion 
We evaluated a new treatment for thumb base OA with inser-
tion of an Artelon CMC spacer and compared it to trapezium 
excision with tendon interposition arthroplasty. The study had 
several strengths: it was controlled, randomized, and observer-
blinded—i.e. the observers carrying out the follow-up investi-
gations were not informed about which surgical procedure the 
individual patient obtained—and included a relatively large 
number of patients treated at 7 clinics.
The new surgical technique with the Artelon CMC spacer, 
however, involved a challenging factor for the study. 3 tech-
niques for interposition arthroplasty were used in the con-
trol group, as it was decided that each investigator should 
use the technique that he or she was most familiar with. This 
means that all investigators had long experience of tendon 
arthroplasty. In contrast, all but one of the investigators had 
no previous experience of the Artelon CMC spacer. There are 
a few important differences between the two surgical tech-
niques that may have had an effect on the study. (1) In tendon 
arthroplasty, a simultaneous OA in the STT joint could be 
accepted since the trapezial bone is removed. Thus, careful 
assessment of a potential concomitant OA of the STT joint 
is not crucial. In contrast, in treatment with the Artelon CMC 
spacer a thorough pre-treatment evaluation to exclude a com-
bined OA is important in order to achieve full pain relief. 
(2) Most surgeons do not use antibiotics in connection with 
tendon arthroplasty, but, as in other surgical procedures with 
joint implants, the use of antibiotics is recommended in treat-
ment with the Artelon CMC spacer. The lack of preoperative 
antibiotics appears to be important. 5 of the 6 patients from 
whom the spacer was removed before 1 year did not receive 
antibiotics. 2 of them had clinical symptoms of infection, but 
cultures on these explants were negative. However, delayed 
infection (defined as a delay of 3–24 months) is characterized 
by subtle signs and symptoms that are sometimes not even 
suggestive of infection (Zimmerli 2006), i.e. the diagnosis of 
prosthetic joint-associated infections is difficult and in many 
patients the only symptom may be pain (Anguita-Alonso et 
al. 2005). The infectious agent may be present exclusively 
as a device-associated biofilm (Zimmerli 2006, Esposito and 
Leone 2008). (3) Independent evaluation of the postoperative 
radiographs revealed that the amount of bone removed from 
the trapezial bone differed. The postoperative appearance on 
radiographs ranged from a large resection of the trapezium to 
an almost invisible resection, indicating that the surgical tech-
nique differed between the surgeons. In some patients also the 
opposite, metacarpal, joint surface was incorrectly removed. 
The importance of training may have been underestimated. 
The above factors may have been the cause of the high rate of 
deviations from the protocol in this study. 
In a previous pilot study with only 1 clinic involved, pinch 
strength after Artelon CMC spacer implantation was found to 
be statistically significantly greater than after tendon interpo-
sition arthroplasty (Nilsson et al. 2005). This result could not 
be confirmed in the present study. To evaluate the influence 
of protocol deviations, a per-protocol analysis was also car-
ried out, including only patients without STT OA changes 
and those in the spacer group who received antibiotics. In 
this analysis, the difference in tripod pinch strength between 
groups after 1 year was 1.4 kg after adjustment for baseline 
values (Table). With limited statistical power, however, the 
difference did not reach statistical significance (p = 0.06). In 
the power calculation performed before the start of the study, a 
difference between groups of 1 kg in tripod pinch strength was 
considered clinically relevant. 
Trapezium excision with tendon interposition arthroplasty 
is considered to be the method of choice by most authors 
for  surgical  treatment  of  thumb  base  OA.  However,  many 
patients experience very long rehabilitation time after surgery 
and impaired pinch strength. The control group in this study 
showed better results in terms of complications, pain relief, 
and pinch strength than those reported in the literature. How-
ever, it still seems justified to try to improve the surgical treat-
ment of this single joint disease in which only the CMC joint 
is affected. Preservation of the length of the first ray including 
the STT joint is preferable and ought to provide an anatomical 
base for better thumb function. 
Previous attempts to use total joint replacements of the CMC 
joint have encountered problems with instability and implant 
dislocation. Regarding the cemented SR trapeziometacarpal 
prostheses, only 40% (8/19) of patients were found to main-
tain an excellent or good result 33 months after surgery (Perez-
Ubeda et al. 2003). Also, previous efforts to replace the CMC 
joint  with  implants  made  from  polymers  such  as  silicone, 
expanded  polytetrafluoroethylene  (ePTFE),  polypropylene, 
and collagen have been associated with disadvantages. The use 
of Silastic trapezial implants is associated with wear, deforma-
tion of the implant, and foreign body reactions (Karlsson et al. 
1992). Pellegrini and Burton (1986) found a 25% failure rate 
with silicone implants. Reactions following ePTFE implants 
have been reported in four-fifths of the patients (Greenberg 
et al. 1997). Muermans and Coenen (1998) compared Gore-
Tex and polypropylene (Marlex) implants with trapezial exci-
sion  ECRL-tendon  interposition.  The  Marlex  implant  was 
well tolerated, but Gore-Tex implants were associated with 
synovitis, characterized by pain and osteolysis in one-third of 
the patients. Belcher and Zic (2001) compared trapeziectomy 
alone with interposition of porcine dermal collagen xenograft 
(Permacol).  The  study  was  terminated  prematurely  due  to 
adverse reactions. 
In the present study, the stability of the CMC-I joint was 
good in both groups. The range of motion was good, as in the 
pilot study (Nilsson et al. 2005), in spite of the ligament rein-
forcement in the spacer procedure producing a firm fixation 
between the metacarpal base and os trapezium. There was no 
statistically significant difference between the groups regard-
ing palmar and radial abduction, or regarding retroposition of Acta Orthopaedica 2010; 81 (1): 237–244  243
the thumb. Thus, flattening of the hand was not a problem, sup-
porting the idea that the Artelon CMC spacer permits motion 
between the metacarpal bone and the implant. 
In the total group of spacer patients, including also those 
with STT changes and lack of antibiotics, a number of patients 
experienced  pain  and  swelling  at  the  site  of  implantation. 
Thus, the reported complications in this group were related to 
presence of pain, which was the main cause of removal of 6 
implants during the 1-year follow-up. In 6 of the other patients 
who reported pain at 1 year, the CMC spacer has later been 
removed and a tendon arthroplasty performed. 9 of these 12 
patients did not receive antibiotics. 4 of the later 6 implants, 
explanted after the 1-year follow-up, were available for his-
tological analysis. In 3 cases a general inflammatory reaction 
was noted in the surrounding soft tissue, but not specifically 
located at the Artelon material. This is consistent with the 
results from the 6 first explants. There were no complications 
of pain in the control group. An overall evaluation of all rel-
evant factors indicated that in 3 cases the symptoms leading to 
explantation could be due to deviations from the recommended 
surgical procedure, and in 1 case the preoperative radiograph 
showed STT OA. Thus, in the latter case pain relief could not 
be expected from treatment of the CMC-OA only. In 1 case, 
the implant had loosened from its fixation to the trapezial bone 
after a heavy lift. The revision procedures included excision 
of both the implant and the trapezium, followed by prosthe-
sis surgery in 1 case, and conversion to a tendon interposition 
arthroplasty in 4 cases. All but one of these cases obtained 
a good result after this procedure, comparable with primary 
tendon arthroplasty.  Adverse tissue reactions around implants 
could be due to poor fixation of the implant, causing mechani-
cal irritation or a foreign-body reaction to the material. Choung 
and Tan (2008) have reported a case with pain and swelling in 
the region of the thumb base after implantation of an Artelon 
CMC spacer. A biopsy showed signs of inflammation with the 
presence of multinucleated giant cells consistent with foreign 
body reaction. The chemical and physical properties of the 
biomaterials themselves may lead to chronic inflammation, 
whereas motion at the implant site by the biomaterial may also 
produce chronic inflammation (Ratner et al. 1996). Thus, the 
symptoms and the histological results described by Choung 
and Tan (2008) may be caused by poor fixation of the spacer, 
indicated by the radiograph showing erosion around the screw 
heads—which would be consistent with screw movements.
In summary, comparison of a new surgical technique with a 
well-proven technique involves a challenge, including a clear 
risk of protocol deviations. The intention-to-treat analysis of 
tripod pinch strength, the primary outcome measure, did not 
show any statistically significant superiority of the Artelon 
CMC spacer over tendon interposition arthroplasty. A thorough 
patient selection, i.e. exclusion of cases with STT changes and 
proper use of preoperative antibiotics, appears to be important 
for the results. Surgery with the Artelon CMC spacer is tissue-
preserving, as it spares most of the trapezium and does not 
require tendon harvest. In addition, the CMC spacer procedure 
permits the future use of other surgical methods, if required. 
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